Predictors for Post-treatment Biopsy Outcomes after SBRT

Predictors for Post-treatment Biopsy Outcomes after Prostate Stereotactic Body Radiotherapy (2021, MSK study)

"Highlights

• SBRT dose levels of 35–37.5 Gy of SBRT were associated with a higher likelihood of a positive post-treatment biopsy at 2 years.
• Two-year positive post-treatment biopsies pre-dated the development of PSA failure in the majority of these patients.
• Among patients with positive post-treatment biopsies, the PSA level at the time of 2-year biopsy was ≤ 1.00 in 52.5% of patients.
• Patients with a positive biopsy had a significantly higher cumulative incidence of BCR at five years compared to patients who had a negative post-RT biopsy (57% versus 7%; p<0.001).

Abstract

Purpose

To investigate predictors associated with post-treatment biopsy outcomes after stereotactic body radiotherapy (SBRT) for localized prostate cancer.

Materials and methods
257 patients treated with prostate SBRT to dose levels of 32.5 Gy to ≥40 Gy in 5–6 fractions underwent a post-treatment biopsy performed approximately two years after treatment to evaluate local control status. 73 had% intermediate-risk disease (n=187) and the remaining 17% (n=43) and 10% (n=27) had low-risk and high-risk disease, respectively.

Results
The incidence of positive, negative, and treatment-effect post-treatment biopsies were 15.6%, 57.6%, and 26.8%, respectively. The incidence of a positive biopsy according to dose was 37.5% (n=9/24), 21.4% (n=6/28), 19.4% (n=6/31), and 10.9% (n=19/174) for 32.5 Gy, 35 Gy, 37.5 Gy, and ≥40 Gy, respectively. In a multivariable model, patients treated with SBRT doses of <40 Gy and those with unfavorable-intermediate-risk or high-risk disease had higher likelihood of a positive post-treatment biopsy. A positive post-SBRT biopsy was associated with a significantly higher likelihood of subsequent PSA relapse at five years (Positive biopsy: 57%, 95% CI: 29-77% compared to negative biopsy: 7%, 95% CI: 3-14%; p<0.001).

Conclusion
Based on two-year post-SBRT biopsies, excellent tumor control was achieved when dose levels of 40 Gy or higher were used. Standard SBRT dose levels of 35–37.5 Gy were associated with a higher likelihood of a positive post-treatment biopsy. Two-year positive post-treatment biopsies pre-dated the development of PSA failure in the majority of patients.
"

[Emphasis mine]

Djin
69 yr at Dx, BPH x 20 yr, 9 (!) neg. Bx
2013 TURP for BPH (90-->30 g) no PCa
6-6-17 Nodule (R) + PSA on finasteride: 3.6-->4.3
Bx #10: 2/14 cores: G10 (5+5) 50% RB, G9 (4+5) 3% RLM, nodule neg
Bone scan, CTs: neg, 8-7-17 open RP @Duke, neg frozen sections, nerves spared
SM EPE BNI LVI SVI LNI(16): neg, PNI+, pT2c pN0 R0 MX, G9 (4+5) 5%, 64 g
Decipher 0.37 Low Risk, PSA 0.010 (3m)…0.037 (3y 4m)

Post Edited (DjinTonic) : 2/16/2021 8:06:26 AM (GMT-7)

Very interesting. Thanks, Djin.

I recall seeing studies where there was more toxicity from SBRT over 36 gy. I guess that will be an area of concern and more study.

What is a "treatment-effect" biopsy?
DOB: May 1944
In Active Surveillance program at Johns Hopkins
Strict protocol of tests, including PHI, DRE, MRI, and biopsy.
Six biopsies from 2009 to 2019. Numbers 1, 2, and 5 were negative. Numbers 3,4, and 6 were positive with 5% Gleason(3+3) found. Last one was Precision Point transperineal.
PSA has varied over the years. Is 4.0 as of September 2019
Hopefully, I can remain treatment free.

ASAdvocate said...
Very interesting. Thanks, Djin.

I recall seeing studies where there was more toxicity from SBRT over 36 gy. I guess that will be an area of concern and more study.

What is a "treatment-effect" biopsy?



I assume it's another term for post-treatment biopsy, i.e., one done for the purpose of evaluating the efficacy of (non-surgical) treatment.

Clearly we expect toxicities to increase with total dosage. A recent paper on SBRT for high-risk said the optimal dosage needs to be established with trials.

Djin

Post Edited (DjinTonic) : 2/16/2021 10:35:58 AM (GMT-7)

From the Full Text:

"Our findings highlight the importance of using higher SBRT dose levels, which are
associated with improved local control as demonstrated on routine post-treatment biopsies. Patients who received >40 Gy had a significantly lower rate of a positive biopsy compared to those who received lower radiation dose levels. The prognostic significance of a positive posttreatment biopsy after definitive prostate radiotherapy is well-recognized. Post-treatment biopsy data from several cohorts of patients treated with external beam radiotherapy indicate that residual prostate cancer cells are seen at 2–3 years after completion of therapy in 20–40% of men clinically without evidence of biochemical or clinical recurrence [11, 12, 14]. We reported our long-term experience of patients treated with IMRT conventionally-fractionated external beam radiotherapy, and noted a strong association of local tumor control based on post-treatment biopsies with long-term distant metastases-free survival and cause-specific survival outcomes.
We also showed two-year positivity was associated with eventual biochemical failure, disease-free survival, distant metastasis, and cause-specific survival outcomes [14,15].
In contrast to PSA post-treatment assessments, which could reflect the status of regional or micrometastatic disease, the efficacy of a local treatment intervention may be better evaluated withpathologic confirmation from a post-treatment biopsy. The post-treatment PSA nadir levels or biochemical relapse-free survival outcomes may not reflect the local tumor status after treatment.
The PSA nadir plus 2 definition for this reason could be misconstrued to suggest that the rising PSA profile prior to reaching the defined threshold of a biochemical relapse is not concerning for residual local disease. In our reported experience [7] among patients with positive biopsies, only 2/21 or 9.5 % had a documented nadir plus 2 PSA failure at the time of biopsy, while the remaining patients manifested a positive biopsy prior to biochemical failure. In the current report, the majority of patients had PSA levels < 1 ng/ml at the time of the post-treatment biopsy, and only 12.5% of these patients had manifested at the time of the biopsy a biochemical nadir+2 relapse. We also noted that despite pre-biopsy PSA levels of <1ng/ml, the incidence of a positive post-treatment biopsy was as high as 25%. While Kass-Illya and colleagues have reported a lower incidence of a positive biopsy in the setting of low PSA levels, that study was very limited by the fact that the post-treatment biopsy only obtained 2-4 cores from the irradiated prostate which likely under-sampled the gland (13). In contrast to that report, our post-treatment biopsies routinely obtained 14-16 cores representing a more comprehensive sampling of the treated gland"